Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02258451
Title Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Bayer
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus + Exemestane

Radium Ra 223 dichloride

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.